RYR1 and Parkinson disease: CPNQ targets huntingtin and α-synuclein to lower their pathological effects in cellular models of Huntington’s and Parkinson’s diseases, respectively (55), and we show here that this compound significantly inhibited only RyR1 (with an inhibitory trend on RyR2) at low [Ca2+].